Stifel Nicolaus Cuts Boston Scientific (NYSE:BSX) Price Target to $85.00

Boston Scientific (NYSE:BSX) had its target price trimmed by Stifel Nicolaus from $90.00 to $85.00 in a research report sent to investors on Tuesday morning, MarketBeat reports. The firm currently has a buy rating on the medical equipment provider’s stock.

Several other equities analysts have also commented on BSX. Wells Fargo & Company dropped their price target on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Citigroup dropped their price target on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. BTIG Research reiterated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, February 4th. Robert W. Baird dropped their price target on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and issued a $112.00 price target on shares of Boston Scientific in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $93.91.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $65.89 on Tuesday. The firm has a market capitalization of $97.93 billion, a P/E ratio of 27.57, a P/E/G ratio of 1.03 and a beta of 0.78. Boston Scientific has a 52 week low of $59.38 and a 52 week high of $109.50. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The firm’s 50 day moving average is $68.71 and its two-hundred day moving average is $86.02.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The firm’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts forecast that Boston Scientific will post 3.36 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Several large investors have recently modified their holdings of BSX. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific in the third quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp boosted its holdings in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares during the period. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $26,000. Finally, Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $26,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat estimates: Boston Scientific reported $5.20B in sales (up ~11.6%) and adjusted EPS of $0.80, topping consensus and showing broad demand across key cardiovascular franchises. This underpins the bullish view on organic growth drivers. Boston Scientific announces results for first quarter 2026
• Positive Sentiment: Market reaction / reset thesis: Some analysts and outlets framed the guidance cut as a constructive “reset” that creates a buying opportunity if management executes on long-term initiatives; that framing helped shares recover after the release. Boston Scientific Just Slashed Guidance and Wall Street Followed. Is the Pullback a Buying Opportunity?
• Neutral Sentiment: Analysts cut targets but largely kept bullish ratings: Multiple firms trimmed price targets (Truist, Baird, Needham, Jefferies, Barclays) while maintaining buy/outperform calls — signaling shorter-term caution but continuing confidence in longer-term upside. Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings
• Neutral Sentiment: Broker commentary called the guidance cut “prudent” with a Q2 trough expected; analysts are modeling a weaker near term but still see recovery later in 2026. That supports mixed near-term sentiment but keeps longer-term forecasts intact. Boston Scientific 2026 Guidance Cut ‘Prudent,’ Q2 Trough Expected, RBC Says
• Negative Sentiment: Guidance cut: Management trimmed FY2026 EPS and revenue guidance below Street consensus and signaled softer near-term procedure volumes in some product lines — the primary reason for the re-rating and analyst target cuts. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Legal risk and class-action notices: Multiple law firms have announced investigations and class-action filings alleging misstatements around procedure demand and disclosures; this raises potential litigation costs and short-to-medium-term headline risk. BOSTON SCIENTIFIC ALERT: Bragar Eagel & Squire, P.C. is Investigating Boston Scientific Corporation

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.